PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma
Jiaxin Cao(Sun Yat-sen University), Hongyun Zhao(Sun Yat-sen University)
Cited by 4
Related Papers
Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth
|Nature Metabolism|2022|155
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
|Cellular and Molecular Immunology|2023|65